Tranexamic acid in chronic urticaria

Phase 2

• Conditions: chronic urticaria.; Other urticaria; L50.8

• Registration Number: IRCT20220205053947N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 4 April 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Patients older than 12 years old
Patients with spontaneous chronic urticaria, according to the criteria of the European Academy of Allergology and Clinical Immunology (EAACI) in agreement with the European Dermatology Forum (EDF), and the World Allergy Organization (WAO), corresponding to an association of the following symptoms: urticarial eruptions and/or recurrent angioedema for at least 6 weeks

Exclusion Criteria

Urticaria associated with a specific systematic disease including cutaneous and systemic mastocytosis
Urticarial vasculitis
Autoinflammatory diseases associated with cryopyrin
Bradykinin angioedema
Isolated angioedema whose origin is not clearly attributable to spontaneous chronic urticaria
Presence of a contraindication to Tranexamic Acid and to Cetirizine such as any history of thromboembolic events as pulmonary thromboembolism and deep vein thrombosis
Coagulopathy.
Unwillingness of the patients or their legal guardians to participate in the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Chronic Urticaria Quality of Life. Timepoint: before intervention and 2 weeks after intervention. Method of measurement: CU-QoL questionnaire.;Severity of Chronic Urticaria. Timepoint: before intervention and 2 weeks after intervention. Method of measurement: UAS7 questionnaire.;Level of D-dimer. Timepoint: before intervention and 2 weeks after intervention. Method of measurement: ELISA.